FDA Grants Rolling Review for QTORIN Rapamycin NDA in Rare Lymphatic Malformation

Palvella Therapeutics has received FDA authorization to submit its New Drug Application (NDA) for QTORIN™ rapamycin under the agency’s rolling review program, advancing the company’s effort to bring the first approved treatment to patients with microcystic lymphatic malformations (microcystic LMs).

The decision follows positive Phase 3 SELVA trial (NCT06239480) results and allows FDA to begin reviewing completed sections of the application before the full NDA is submitted. Palvella expects to complete the NDA submission during the second half of 2026.

QTORIN rapamycin has already received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, reflecting the significant unmet medical need in microcystic LMs and the therapy’s potential clinical benefit.

Addressing a Rare Disease with No Approved Therapies

Microcystic lymphatic malformations are rare genetic vascular disorders driven by abnormal activation of the PI3K/mTOR signaling pathway. The condition causes malformed lymphatic vessels to extend into the skin, leading to chronic leakage, bleeding, recurrent infections, cellulitis, pain, and repeated hospitalizations.

The disease often progresses over time and rarely resolves spontaneously. Current management relies on surgery, laser therapy, or sclerotherapy, but recurrence remains common and many patients require multiple procedures. Systemic mTOR or PI3K inhibitors may provide benefit in some cases but can be limited by long-term safety concerns and challenges in delivering adequate drug exposure to affected skin, particularly in pediatric patients.

QTORIN rapamycin takes a different approach by delivering rapamycin directly to diseased skin tissue. This localized treatment strategy targets overactive mTOR signaling at the site of disease while minimizing systemic drug exposure.

According to the company, more than 30,000 people in the United States are living with diagnosed microcystic LMs, yet no FDA-approved therapies currently exist.

Phase 3 Data Supports Regulatory Submission

The NDA is supported by results from the Phase 3 SELVA study, which demonstrated clinically meaningful benefits in patients with microcystic LMs. While Palvella has not yet disclosed complete regulatory review timelines, the positive trial findings formed the basis for the company’s NDA filing strategy and supported the regulatory designations previously granted by FDA.

Rolling review is available to therapies with Fast Track or Breakthrough Therapy designation that address serious conditions and unmet medical needs. The process allows FDA reviewers to assess sections of an application as they become available, potentially shortening the overall review timeline once the complete NDA is submitted.

Moving Toward Potential Approval

Palvella Founder and Chief Executive Officer Wes Kaupinen said the company remains focused on completing the NDA submission in the second half of 2026 and leveraging its regulatory designations to support an efficient review process.

If approved, QTORIN rapamycin could establish the first FDA-approved standard of care for microcystic lymphatic malformations, providing patients and families with a targeted treatment option for a lifelong condition that currently lacks approved therapies. The upcoming NDA completion and FDA review will represent the next major milestones for the program.

What This Means for Patients

People living with microcystic lymphatic malformations currently have no FDA-approved treatment options and often undergo repeated procedures to manage symptoms. If approved, QTORIN™ rapamycin could become the first targeted therapy specifically for this condition, offering a new treatment option that may control disease symptoms while reducing the burden of invasive interventions.

Reference

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations – Mon, 06/22/2026 – 07:30